NCT06530992

Brief Summary

Because gender-affirming hormone therapy (GAHT) can lead to fertility impairment, current guidelines and treatment recommendations require that patients be informed about the possibility of fertility preservation prior to initiating GAHT. A recent review by our working group analyzed the current data on fertility and fertility preservation in transgender and gender diverse people. Several studies were identified that evaluated semen quality before and during GAHT in trans women compared to reproductive men. All studies showed a significant reduction in semen quality even before GAHT. In addition, one study found evidence that constant wearing of tight underwear and tucking was associated with a reduction in motile sperm concentration to \<5 mill/ml. Tucking is a method of avoiding crotch bulge through the penis and testicles by placing the penis backwards between the legs and optionally pushing the testicles into the groin canals. These positions are fixed with tight-fitting underwear or gaffs. Whether tucking or the wearing of tight underwear is the determining factor for impaired semen quality even before the start of GAHT and whether there is reversibility remains unclear and will be investigated in the present study. The study is designed as a prospective case-control study with a total sample size of n = 40 trans women. All patients with gender incongruence presenting to the University Clinic for Gynecology, Endocrinology and Reproduction Innsbruck before starting GAHT are eligible to participate. Trans women (n = 20) who practice tucking or wear tight underwear will be included and trans women (n = 20) who do not practice tucking will be included as a control group. At Time 1, after 2-7 days of abstinence, all participants will provide a semen sample for a spermiogram, a venous blood sample will be taken, and quality of life will be assessed using a questionnaire. The frequency and duration of tucking or wearing tight underwear, ejaculation frequency, demographic data such as BMI, nicotine use, alcohol and drug use, medication use, underlying medical conditions, previous surgeries, etc. are also recorded. Participants in the study group are then asked to abstain tucking for at least 73 days. After 2-7 days of sperm abstinence, another semen sample is taken at time 2, a venous blood sample is taken, and quality of life is assessed. At this point, depending on the participant's wishes, there is the option of sperm cryopreservation for fertility preservation prior to starting GAHT. Spermiograms are performed under standardized conditions according to current WHO guidelines.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
43mo left

Started Jul 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress34%
Jul 2024Dec 2029

Study Start

First participant enrolled

July 17, 2024

Completed
6 days until next milestone

First Submitted

Initial submission to the registry

July 23, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

July 31, 2024

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2029

Expected
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2029

Last Updated

July 31, 2024

Status Verified

July 1, 2024

Enrollment Period

5 years

First QC Date

July 23, 2024

Last Update Submit

July 29, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • semen concentration

    Semen quality defined by semen concentration, motility and total volume with and without tucking

    3 months

  • semen motility

    Semen quality defined by semen concentration, motility and total volume with and without tucking

    3 months

  • semen total volume

    Semen quality defined by semen concentration, motility and total volume with and without tucking

    3 months

Secondary Outcomes (5)

  • LH

    3 months

  • FSH

    3 months

  • estradiol

    3 months

  • testosterone

    3 months

  • quality of life assessment

    3 months

Study Arms (2)

tucking

trans women who practice tucking

Other: tucking break

no tucking

trans women who do not practice tucking

Interventions

All participants will provide a semen sample for sperm analysis after 2-7 days of abstinence from ejaculation, a venous blood sample will be taken at the same time, and quality of life will be assessed using a questionnaire. Participants in the study group are then asked to refrain from tucking or wearing tight underwear for at least 73 days. At least 73 days (10.5 weeks) after the first spermiogram, another semen collection is scheduled after 2-7 days of abstinence from ejaculation for the preparation of a spermiogram, a venous blood sample is taken at the same time, and quality of life is assessed in all participants. At this point, depending on the participant's wishes, it is possible to perform sperm cryopreservation for fertility preservation before starting gender affirming hormonal treatment.

tucking

Eligibility Criteria

Age18 Years - 50 Years
Sexmale(Gender-based eligibility)
Gender Eligibility Detailsfemale gender identity
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Female transgender patients between the ages of 18 to 50 years of age who are seen at the University Clinic for Gyn. Endocrinology and Reproductive Medicine of the Medical University of Innsbruck. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy.

You may qualify if:

  • Female transgender patients between the ages of 18 to 50 years of age who are seen at the University Clinic for Gyn. Endocrinology and Reproductive Medicine of the Medical University of Innsbruck. Patients must have met the eligibility and readiness criteria for gender-affirming hormone therapy

You may not qualify if:

  • Ongoing GAHT gender affirming genital surgery Hypogonadism Diabetes mellitus Cystic Fibrosis Varicocele Cryptorchism Post-sterilization Incapacity to consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University clinic for Gynecological Endocrinology and Reproductive Medicine Department of Gynecology Medical University of Innsbruck

Innsbruck, Austria

RECRUITING

MeSH Terms

Conditions

Gender DysphoriaInfertility

Condition Hierarchy (Ancestors)

Sexual Dysfunctions, PsychologicalMental DisordersGenital DiseasesUrogenital Diseases

Central Study Contacts

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2024

First Posted

July 31, 2024

Study Start

July 17, 2024

Primary Completion (Estimated)

July 1, 2029

Study Completion (Estimated)

December 1, 2029

Last Updated

July 31, 2024

Record last verified: 2024-07

Locations